<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314557</url>
  </required_header>
  <id_info>
    <org_study_id>18/532-O_P</org_study_id>
    <nct_id>NCT04314557</nct_id>
  </id_info>
  <brief_title>Renal Arterial Denervation in Sympathetic Dysautonomia</brief_title>
  <acronym>RANSOM</acronym>
  <official_title>Renal Arterial Denervation in Sympathetic Dysautonomia: RANSOM REGISTRY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Carlos Hospital, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Carlos Hospital, Madrid, Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RANSOM registry is considered as a collection of data with the ultimate purpose of
      gathering information about the effect of renal denervation in patients of the investigator's
      center and evaluating the results within the usual clinical practice.

      The general objective of the study is to evaluate the clinical results (blood pressure,
      quality of life and levels of catecholamines) as well as safety of renal sympathetic
      denervation in hypertensive patients, at least in treatment with an antihypertensive drug and
      with increased variability, considering as such a standard deviation&gt; 10 mmHg for systolic BP
      and&gt; 5 for diastolic BP of its blood pressure levels, measured by ABPM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Change in the descent of Systolic BP in orthostatism</measure>
    <time_frame>12 months</time_frame>
    <description>BP Variability decrease, any (yes/no).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the descent of Systolic BP in orthostatism.</measure>
    <time_frame>12 months</time_frame>
    <description>BP Variability decrease &lt; 25 percent (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of quality of life and subjective perception of well-being.</measure>
    <time_frame>12 months</time_frame>
    <description>Short form 12, questionaire (0-100, the higher the better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of blood pressure control, average levels and variability</measure>
    <time_frame>12 months</time_frame>
    <description>AMPA measure mean PA levels (numeric)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety end points</measure>
    <time_frame>12 months</time_frame>
    <description>MACE (death,bleeding, renal failure-yes/no)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertension</condition>
  <condition>Renal Denervation</condition>
  <condition>Increased Variability</condition>
  <condition>Blood Pressure Disorders</condition>
  <condition>Blood Pressure Variability</condition>
  <condition>Sympathetic Dysautonomia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal denervation</intervention_name>
    <description>Spyral device. Bilateral renal denervation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All comers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients included in a prospective manner must sign an informed written consent
             and meet ALL of the following criteria that are typical of the procedure according to
             the protocol of our center:

          -  Be considered adequate and eligible by the group of doctors responsible for the
             patient and by the multidisciplinary team of the study. Over 18 years, not pregnant.

          -  Poorly controlled arterial hypertension, under treatment with at least one
             antihypertensive drug.

          -  In addition, poorly controlled hypertension + increased variability, considering as
             such a standard deviation&gt; 10 mmHg for systolic BP and&gt; 5 for the diastolic BP of
             patient´s blood pressure levels, measured by ABPM.

          -  Renal arteries anatomy suitable for the procedure, considered by CT, MRI, ultrasound
             or angiography.

          -  Some criteria of dysautonomia, following the consensus of the American Autonomous
             Society (AAS) and the European Federation of Autonomous Societies (EFAS) of 2018.

        or supine HTN. Defined as sBP ≥ 140 mmHg and / or dBP ≥ 90 mmHg, measured at least after 5
        minutes of supine rest. Moderate forms (160-179 mmHg or dBP of 100-109 mmHg) or severe will
        preferably be included. (sBP≥ 180 mmHg and / or dBP ≥ 110 mmHg). Mild forms will be
        considered in conjunction with symptoms or other findings (ABPM) or nighttime HTN.
        Considered as such one that does not fall more than 10% compared to the daytime BP or even
        rises (riser). They will be considered in conjunction with symptoms or other findings (eg
        ABMP).

          -  If the foregoing is not fulfilled, marked orthostatism (&gt; 30 mmHG in sBP and / or&gt;
             10mmHG in dBP).

          -  Life expectancy exceeding one year (not presenting terminal illness or any health
             condition for which a survival of less than one year is estimated).

        Exclusion Criteria:

          -  eGFR &lt;30 mL / min / 1.73m2.

          -  Monoxidin treatment.

          -  Impossibility of informed consent by the patient or legal representative.

          -  Impossibility for follow-up at least 1 year.

          -  Do not fulfill inclusion criteria, assessed by the multidisciplinary team.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan J Núñez Gil, MD</last_name>
      <phone>0034625585461</phone>
      <email>ibnsky@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Oscar Vedia, MD</last_name>
      <email>oscarvediacruz@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://manuals.medtronic.com/manuals/main/en_ES/manual/index</url>
    <description>Spyral device description/label</description>
  </link>
  <reference>
    <citation>Catalá-López F, Sanfélix-Gimeno G, García-Torres C, Ridao M, Peiró S. Control of arterial hypertension in Spain: a systematic review and meta-analysis of 76 epidemiological studies on 341 632 participants. J Hypertens. 2012 Jan;30(1):168-76. doi: 10.1097/HJH.0b013e32834d30ec. Review.</citation>
    <PMID>22025240</PMID>
  </reference>
  <reference>
    <citation>Kotseva K, De Bacquer D, De Backer G, Rydén L, Jennings C, Gyberg V, Abreu A, Aguiar C, Conde AC, Davletov K, Dilic M, Dolzhenko M, Gaita D, Georgiev B, Gotcheva N, Lalic N, Laucevicius A, Lovic D, Mancas S, Miličić D, Oganov R, Pajak A, Pogosova N, Reiner Ž, Vulic D, Wood D, On Behalf Of The Euroaspire Investigators. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol. 2016 Dec;23(18):2007-2018. doi: 10.1177/2047487316667784. Epub 2016 Sep 27.</citation>
    <PMID>27638542</PMID>
  </reference>
  <reference>
    <citation>Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475.</citation>
    <PMID>30165516</PMID>
  </reference>
  <reference>
    <citation>Hering D, Grassi G. Effects of renal denervation on short-term blood pressure variability: lack of meta-analytic evidence. J Hypertens. 2017 Sep;35(9):1780-1781. doi: 10.1097/HJH.0000000000001397.</citation>
    <PMID>28767486</PMID>
  </reference>
  <reference>
    <citation>Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, Eschlboeck S, Grassi G, Hilz MJ, Kaufmann H, Lahrmann H, Mancia G, Mayer G, Norcliffe-Kaufmann L, Pavy-Le Traon A, Raj SR, Robertson D, Rocha I, Struhal W, Thijs R, Tsioufis KP, van Dijk JG, Wenning GK. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018 Aug;28(4):355-362. doi: 10.1007/s10286-018-0529-8. Epub 2018 May 15. Review.</citation>
    <PMID>29766366</PMID>
  </reference>
  <reference>
    <citation>Núñez-Gil IJ. Protocolo Asistencial de denervación renal percutánea mediante radiofrecuencia. Hospital Clínico San Carlos 2016.</citation>
  </reference>
  <reference>
    <citation>Núñez-Gil IJ, García-Donaire JA, Vedia O, Abad-Cardiel M, Martell-Claros N, Fernández-Ortiz A. [Initial experience with a multi-electrode catheter in renal denervation. A technique that has come back to stay?]. Hipertens Riesgo Vasc. 2019 Jul - Sep;36(3):166-168. doi: 10.1016/j.hipert.2019.04.002. Epub 2019 May 31. Spanish.</citation>
    <PMID>31160234</PMID>
  </reference>
  <reference>
    <citation>Travieso-Gonzalez A, Núñez-Gil IJ, Riha H, Donaire JAG, Ramakrishna H. Management of Arterial Hypertension: 2018 ACC/AHA Versus ESC Guidelines and Perioperative Implications. J Cardiothorac Vasc Anesth. 2019 Dec;33(12):3496-3503. doi: 10.1053/j.jvca.2019.03.068. Epub 2019 Apr 3. Review.</citation>
    <PMID>31078374</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Carlos Hospital, Madrid, Spain</investigator_affiliation>
    <investigator_full_name>IVAN J NUÑEZ GIL</investigator_full_name>
    <investigator_title>Principal Investigator. Attending Physician. MD, PhD, FESC</investigator_title>
  </responsible_party>
  <keyword>Sympathetic dysautonomia</keyword>
  <keyword>Blood Pressure Variability</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Renal denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

